直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
Victoria A. Randall, Ph.D.
Partner
More
vCard
  • 1 London Bridge
  • London, United Kingdom SE1 9BG
+44 (0)20 7864 2812
victoria.randall@finnegan.com victoria.randall@finnegan.com

Victoria A. Randall, Ph.D.

Partner

  • +44 (0)20 7864 2812 +44 (0)20 7864 2812
  • victoria.randall@finnegan.com victoria.randall@finnegan.com
  • 1 London Bridge
  • London, United Kingdom SE1 9BG
  • vCard

Victoria Randall is a chartered UK patent attorney and a European patent attorney. With a background in biomedical sciences, she works with a diverse portfolio of clients, including global pharmaceuticals and startup biotechnology companies. Victoria is the recipient of the "IP Rising Star" Award 2023 from Women in Business Law EMEA.

Victoria entered the patent profession in 2009 and joins Finnegan having previously worked for two large UK firms and a boutique firm. She has acquired extensive experience in a broad range of life sciences subject matter. Her areas of interest include personal medicine, antibody technologies, antisense therapeutics, blood products, vaccines, gene manipulation, and stem cell culture methods.

Victoria enjoys all aspects of prosecution, including drafting, filing, examination, and grant procedures. She has experience with oppositions and appeals, representing both patentee and opponent at Oral Proceedings before the European Patent Office (EPO). She has managed large, complex portfolios protecting high-value pharmaceuticals. Victoria has experience prosecuting supplementary protection certificates and has been involved in litigation proceedings before the UK High Court.

Victoria has a first class degree in Biomedical Sciences from The University of Sheffield and a Ph.D. from University College London. She conducted research at the Institute of Child Health at Great Ormond Street Hospital, where she focused on the genetic interactions underlying two congenital syndromes.

Experience

Comprehensive patent transactions and strategic counseling for one of the largest pharmaceutical companies in the world

Finnegan is lead and preferred IP transactions counsel for one of the largest pharmaceutical companies in the world, handling more than 50 diligence projects each year, including all IP and related transactional aspects of the matters. The transactions span the full gamut of technologies from small molecule through biologics such as antibodies, oligonucleotides, and gene therapies. Finnegan also provides extensive assistance with post-deal integration procedures and subsequent global prosecution and portfolio strategy, ensuring a seamless transition of IP assets to the company and maximum value from acquired IP.

Insights

Workshop

Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law

Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law Protecting Innovation in the Life Sciences: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law

May 7, 2026

Cambridge

European IP Blog

T 0137/24 and Securing Effective Protection for Biologics T 0137/24 and Securing Effective Protection for Biologics

1 May 2026

European IP Blog

Precision Breeding in England: Navigating the New Regulatory Framework Precision Breeding in England: Navigating the New Regulatory Framework

9 December 2025

Articles

EPO Referral May Shift Patent Description Amendment Rules

EPO Referral May Shift Patent Description Amendment Rules EPO Referral May Shift Patent Description Amendment Rules

November 4, 2025

Law360

European IP Blog

Colour Drawings at the EPO: What You Need to Know Colour Drawings at the EPO: What You Need to Know

1 October 2025

European IP Blog

Description Amendments in the Spotlight – A Referral to the Enlarged Board in G 1/25 Description Amendments in the Spotlight – A Referral to the Enlarged Board in G 1/25

7 August 2025

More

News

Award/Ranking

Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked

May 28, 2026

Intellectual Asset Management (IAM)

Press Release

Twelve Attorneys Elevated to Finnegan Partnership Twelve Attorneys Elevated to Finnegan Partnership

January 7, 2025

Announcement

Finnegan’s Victoria Randall Receives Women in Business Law “IP Rising Star” Award Finnegan’s Victoria Randall Receives Women in Business Law “IP Rising Star” Award

June 29, 2023

Women in Business Law

Award/Ranking

Finnegan Shortlisted for “German Firm of the Year” by Women in Business Law Awards EMEA Finnegan Shortlisted for “German Firm of the Year” by Women in Business Law Awards EMEA

May 9, 2023

Women in Business Law

Professional Activities

  • European Patent Institute (EPI)
    (Member, 2013-present)
  • Chartered Institute of Patent Attorneys (CIPA)
    (2018-present)
Admissions and Education

Admissions

  • Unified Patent Court (UPC)

Education

Queen Mary, University of London
Certificate, Intellectual Property Law, Merit, 2011
University College London
Ph.D., Molecular Medicine Unit, 2008
The University of Sheffield
B.Sc., Biomedical Sciences, 1st Class Honours, 2004

Victoria's Practices

Global IP Enforcement, Litigation, and Trials
Patent Litigation and Trials
Prosecution and Portfolio Management
Patent Drafting and Prosecution

Victoria's Industries

Life Sciences
Biotechnology
Pharmaceutical

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP